Developer docs
API playgroundTry for free, no card

Search company profiles

RetiSpec

Full company profile

uuid00025bx

Namestring
RetiSpec
Legal namestring
RetiSpec Inc.
Websiteurl
retispec.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

RetiSpec is a Toronto-based medical imaging company developing an AI-driven, point-of-care diagnostic for the early detection of Alzheimer's disease pathology through hyperspectral retinal imaging. Its core product analyzes retinal images captured with existing eye-clinic cameras, extracting more than 100 spectral bands per pixel (versus the three bands in standard RGB imaging) to detect amyloid beta biomarkers via proprietary AI algorithms developed from technology licensed from the University of Minnesota's Center for Drug Design. The platform is positioned as a non-invasive, affordable alternative to PET-based and CSF-based Alzheimer's diagnostics, with the goal of identifying disease years before clinical symptom onset.

The company's go-to-market targets three primary customer segments: eye care providers and clinics (optometrists and ophthalmologists) as the primary channel for routine screening; memory clinics and neurology practices for point-of-care evaluation of at-risk patients; and pharmaceutical/biotech companies using the retinal test to pre-screen participants for Alzheimer's clinical trials, improving recruitment efficiency. RetiSpec entered a strategic collaboration and investment agreement with Topcon Healthcare in April 2024 and closed a $10M USD funding round in July 2024 to advance commercialization, alongside partnerships with VSP Vision, the Global Alzheimer's Platform Foundation, and the Alzheimer's Drug Discovery Foundation.

RetiSpec is currently pre-revenue: its technology is explicitly designated for research use only and is not yet FDA-cleared or commercially available. The business model anticipates recurring revenue via deployment through existing retinal imaging infrastructure in eye clinics, with the ~24-person team structured around AI engineering, clinical operations, regulatory affairs, and business development to support the transition from research validation to commercial launch.

Short descriptiontext

RetiSpec is a Toronto-based medical imaging startup developing an AI-driven hyperspectral retinal imaging platform for non-invasive, early detection of Alzheimer's disease pathology, targeting eye care clinics, memory clinics, and pharmaceutical clinical trial screening.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI retinal imaging, Alzheimer's diagnostics, hyperspectral imaging, neurodegenerative disease detection, medical imaging AI
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Diagnostic Imaging Centers621512
Product category
Medical Imaging Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Research Use Only
TypeSubscription Recurring
Description

RetiSpec's technology is currently for research use only and not yet commercially available. The company closed $10M USD in July 2024 to advance commercialization of its AI-driven eye test for detection of Alzheimer's disease, indicating they are in pre-commercialization stage.

retispec.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

RetiSpec develops an AI-driven diagnostic platform that uses hyperspectral retinal imaging to detect Alzheimer's disease pathology (amyloid beta) years before clinical symptoms emerge. The platform analyzes data from existing retinal imaging cameras already deployed in eye clinics, combining hyperspectral image capture with explainable AI algorithms to deliver non-invasive, point-of-care screening for neurodegenerative disease markers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • RetiSpec's retinal scan demonstrated comparable performance to blood-based biomarkers for predicting brain Aβ pathology in Bio-Hermes-001 study
+2 more records
Product overview1 text field

RetiSpec offers a unified AI-driven diagnostic platform for early Alzheimer's disease detection through retinal imaging. The core offering combines the RetiSpec Hyperspectral Retinal Imaging System (a medical device that captures multi-spectral retinal images) with the RetiSpec AI-Based Retinal Test (software that analyzes these images to detect amyloid beta biomarkers). The solution uses existing retinal imaging cameras found in eye clinics, enhanced with hyperspectral imaging technology and explainable AI algorithms to enable non-invasive early detection of Alzheimer's disease.

Product and service1 record
1RetiSpec AI-Based Retinal Test
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-06-09
Description

RetiSpec was spotlighted by Techonomy in partnership with VSP Vision as one of ten AI and Health Access innovators using technology to expand healthcare access to underserved populations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-30
Description

Topcon Healthcare announced collaboration and investment with RetiSpec to help bring the eye-based AI diagnostic tool to market. This partnership combines Topcon's expertise in eye care technology with RetiSpec's AI capabilities to accelerate commercialization of the Alzheimer's detection solution.

3University of Minnesota's Center for Drug Design
Strategic tierCoreTypeTechnology or Integration
Description

RetiSpec's solution draws on technology developed by Robert Vince, Ph.D., and Swati More, Ph.D., at the University of Minnesota's Center for Drug Design. Professor Vince, inventor of abacavir (Ziagen), and Professor More developed the underlying method of using retinal hyperspectral imaging to detect Alzheimer's disease pathology.

retispec.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

John Dwyer, Co-Founder and President of GAP, has publicly endorsed RetiSpec's technology. RetiSpec's test results are included in the Bio-Hermes database along with brain amyloid PET scan results to advance understanding of retinal imaging's role in Alzheimer's.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Dr. Howard Fillit, MD, Executive Director and CSO of the Alzheimer's Drug Discovery Foundation, has provided endorsement of RetiSpec's retinal scanner as a unique diagnostic tool with potential to facilitate early diagnosis and improve patient lives.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Dr. Sharon Cohen, Medical Director and Behavioural Neurologist at Toronto Memory Program, has provided endorsement of RetiSpec's technology. Toronto Memory Program and RetiSpec were featured together as a case study on the Davos Alzheimer's Collaborative Blueprint.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

C2N Diagnostics offers the PrecivityAD blood-based test for Alzheimer's amyloid detection, directly competing with RetiSpec in the early Alzheimer's diagnostic space. Both target non-invasive, scalable alternatives to PET imaging, though C2N uses plasma biomarkers rather than retinal imaging.

TypeDirect peer
Description

Quanterix develops ultra-sensitive blood-based biomarker assays for neurodegenerative diseases including Alzheimer's. Both RetiSpec and Quanterix compete in enabling earlier, less invasive detection of Alzheimer's pathology, though via different biological matrices (retina vs. plasma).

TypeDirect peer
Description

iHealthScreen applies AI to retinal images for risk prediction of systemic and neurodegenerative conditions. Both companies share the AI-retinal-imaging approach to non-invasive disease screening and target eye-care providers as the deployment channel.

TypeBroad incumbent
Description

Topcon Healthcare is a global ophthalmic device manufacturer and RetiSpec's strategic partner. As a broad incumbent in retinal imaging hardware, Topcon both enables RetiSpec's distribution and represents a strategic risk if it chooses to internalize competing AI capabilities.

TypeBroad incumbent
Description

Optos manufactures ultra-widefield retinal imaging devices used in eye clinics globally. RetiSpec's solution operates on retinal cameras including those from Optos, making Optos a channel partner and a potential competitor if it bundles its own AI diagnostic offerings.

TypeDirect peer
Description

Notal Vision provides AI-driven home-based retinal monitoring (ForeseeHome) and clinic-based diagnostic imaging services. Both companies apply AI to retinal imaging for disease management and target ophthalmology clinic workflows.

TypeBroad incumbent
Description

icometrix develops AI-based analysis of brain MRI/CT scans for neurological conditions including multiple sclerosis and dementia. Both companies apply AI imaging diagnostics to neurodegenerative disease, although icometrix focuses on brain imaging rather than retinal.

TypeEmerging player
Description

Linus Health offers digital cognitive assessment tools for early detection of cognitive impairment and Alzheimer's. Both companies pursue earlier, accessible detection of neurodegenerative decline, but Linus uses digital pen-and-tablet cognitive tests rather than retinal biomarkers.

TypeEmerging player
Description

Spectral MD applies hyperspectral imaging and AI for wound care diagnostics. While the application area differs, the underlying hyperspectral imaging + AI architecture is technically analogous to RetiSpec's approach, making it a relevant technology peer.

10ADx NeuroSciences
TypeEmerging player
Description

ADx NeuroSciences develops biomarker assays (CSF and blood) for Alzheimer's and other neurodegenerative diseases. Both companies are advancing biomarker-based diagnostics for early Alzheimer's detection, though ADx focuses on biofluid assays rather than retinal imaging.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RetiSpec

Medical Imaging Diagnosticsretispec.com

RetiSpec is a Toronto-based medical imaging startup developing an AI-driven hyperspectral retinal imaging platform for non-invasive, early detection of Alzheimer's disease pathology, targeting eye care clinics, memory clinics, and pharmaceutical clinical trial screening.

What RetiSpec does

RetiSpec is a Toronto-based medical imaging company developing an AI-driven, point-of-care diagnostic for the early detection of Alzheimer's disease pathology through hyperspectral retinal imaging. Its core product analyzes retinal images captured with existing eye-clinic cameras, extracting more than 100 spectral bands per pixel (versus the three bands in standard RGB imaging) to detect amyloid beta biomarkers via proprietary AI algorithms developed from technology licensed from the University of Minnesota's Center for Drug Design. The platform is positioned as a non-invasive, affordable alternative to PET-based and CSF-based Alzheimer's diagnostics, with the goal of identifying disease years before clinical symptom onset.

The company's go-to-market targets three primary customer segments: eye care providers and clinics (optometrists and ophthalmologists) as the primary channel for routine screening; memory clinics and neurology practices for point-of-care evaluation of at-risk patients; and pharmaceutical/biotech companies using the retinal test to pre-screen participants for Alzheimer's clinical trials, improving recruitment efficiency. RetiSpec entered a strategic collaboration and investment agreement with Topcon Healthcare in April 2024 and closed a $10M USD funding round in July 2024 to advance commercialization, alongside partnerships with VSP Vision, the Global Alzheimer's Platform Foundation, and the Alzheimer's Drug Discovery Foundation.

RetiSpec is currently pre-revenue: its technology is explicitly designated for research use only and is not yet FDA-cleared or commercially available. The business model anticipates recurring revenue via deployment through existing retinal imaging infrastructure in eye clinics, with the ~24-person team structured around AI engineering, clinical operations, regulatory affairs, and business development to support the transition from research validation to commercial launch.

RetiSpec firmographics

Firmographics
Name
RetiSpec
Legal name
RetiSpec Inc.
Website
https://retispec.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
RetiSpec is a Toronto-based medical imaging startup developing an AI-driven hyperspectral retinal imaging platform for non-invasive, early detection of Alzheimer's disease pathology, targeting eye care clinics, memory clinics, and pharmaceutical clinical trial screening.
Ownership category
akta.pro rank

RetiSpec industry classification

Industry
Product category
Medical Imaging Diagnostics
NAICS
Diagnostic Imaging Centers (621512)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • AI retinal imaging
  • Alzheimer's diagnostics
  • Hyperspectral imaging
  • Neurodegenerative disease detection
  • Medical imaging AI

Where RetiSpec is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

RetiSpec business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pre-revenue / Research Use Only: RetiSpec's technology is currently for research use only and not yet commercially available. The company closed $10M USD in July 2024 to advance commercialization of its AI-driven eye test for detection of Alzheimer's disease, indicating they are in pre-commercialization stage.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

RetiSpec product offering

Product offering

Core offering

RetiSpec develops an AI-driven diagnostic platform that uses hyperspectral retinal imaging to detect Alzheimer's disease pathology (amyloid beta) years before clinical symptoms emerge. The platform analyzes data from existing retinal imaging cameras already deployed in eye clinics, combining hyperspectral image capture with explainable AI algorithms to deliver non-invasive, point-of-care screening for neurodegenerative disease markers.

Product overview

RetiSpec offers a unified AI-driven diagnostic platform for early Alzheimer's disease detection through retinal imaging. The core offering combines the RetiSpec Hyperspectral Retinal Imaging System (a medical device that captures multi-spectral retinal images) with the RetiSpec AI-Based Retinal Test (software that analyzes these images to detect amyloid beta biomarkers). The solution uses existing retinal imaging cameras found in eye clinics, enhanced with hyperspectral imaging technology and explainable AI algorithms to enable non-invasive early detection of Alzheimer's disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • RetiSpec AI-Based Retinal Test

Quantifiable outcome

  • RetiSpec's retinal scan demonstrated comparable performance to blood-based biomarkers for predicting brain Aβ pathology in Bio-Hermes-001 study
  • +2 more outcomes

Companies that use RetiSpec

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

RetiSpec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

RetiSpec partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, core and major.

  • VSP VisionminorGTM or Marketing Partner · 9 June 2025RetiSpec was spotlighted by Techonomy in partnership with VSP Vision as one of ten AI and Health Access innovators using technology to expand healthcare access to underserved populations.
  • Topcon Healthcare, Inc.coreStrategic or Co-development Partner · 30 April 2024Topcon Healthcare announced collaboration and investment with RetiSpec to help bring the eye-based AI diagnostic tool to market. This partnership combines Topcon's expertise in eye care technology with RetiSpec's AI capabilities to accelerate commercialization of the Alzheimer's detection solution.
  • University of Minnesota's Center for Drug DesigncoreTechnology or IntegrationRetiSpec's solution draws on technology developed by Robert Vince, Ph.D., and Swati More, Ph.D., at the University of Minnesota's Center for Drug Design. Professor Vince, inventor of abacavir (Ziagen), and Professor More developed the underlying method of using retinal hyperspectral imaging to detect Alzheimer's disease pathology.
  • Global Alzheimer's Platform Foundation (GAP)majorStrategic or Co-development PartnerJohn Dwyer, Co-Founder and President of GAP, has publicly endorsed RetiSpec's technology. RetiSpec's test results are included in the Bio-Hermes database along with brain amyloid PET scan results to advance understanding of retinal imaging's role in Alzheimer's.
  • Alzheimer's Drug Discovery FoundationmajorStrategic or Co-development PartnerDr. Howard Fillit, MD, Executive Director and CSO of the Alzheimer's Drug Discovery Foundation, has provided endorsement of RetiSpec's retinal scanner as a unique diagnostic tool with potential to facilitate early diagnosis and improve patient lives.
  • Toronto Memory ProgrammajorStrategic or Co-development PartnerDr. Sharon Cohen, Medical Director and Behavioural Neurologist at Toronto Memory Program, has provided endorsement of RetiSpec's technology. Toronto Memory Program and RetiSpec were featured together as a case study on the Davos Alzheimer's Collaborative Blueprint.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

RetiSpec competitors and assessment

Company assessment

Direct peers

  • C2N Diagnostics: C2N Diagnostics offers the PrecivityAD blood-based test for Alzheimer's amyloid detection, directly competing with RetiSpec in the early Alzheimer's diagnostic space. Both target non-invasive, scalable alternatives to PET imaging, though C2N uses plasma biomarkers rather than retinal imaging.
  • Quanterix: Quanterix develops ultra-sensitive blood-based biomarker assays for neurodegenerative diseases including Alzheimer's. Both RetiSpec and Quanterix compete in enabling earlier, less invasive detection of Alzheimer's pathology, though via different biological matrices (retina vs. plasma).
  • iHealthScreen: iHealthScreen applies AI to retinal images for risk prediction of systemic and neurodegenerative conditions. Both companies share the AI-retinal-imaging approach to non-invasive disease screening and target eye-care providers as the deployment channel.
  • Notal Vision: Notal Vision provides AI-driven home-based retinal monitoring (ForeseeHome) and clinic-based diagnostic imaging services. Both companies apply AI to retinal imaging for disease management and target ophthalmology clinic workflows.

Broad incumbents

  • Topcon Healthcare: Topcon Healthcare is a global ophthalmic device manufacturer and RetiSpec's strategic partner. As a broad incumbent in retinal imaging hardware, Topcon both enables RetiSpec's distribution and represents a strategic risk if it chooses to internalize competing AI capabilities.
  • Optos (Nikon): Optos manufactures ultra-widefield retinal imaging devices used in eye clinics globally. RetiSpec's solution operates on retinal cameras including those from Optos, making Optos a channel partner and a potential competitor if it bundles its own AI diagnostic offerings.
  • icometrix: icometrix develops AI-based analysis of brain MRI/CT scans for neurological conditions including multiple sclerosis and dementia. Both companies apply AI imaging diagnostics to neurodegenerative disease, although icometrix focuses on brain imaging rather than retinal.

Emerging players

  • Linus Health: Linus Health offers digital cognitive assessment tools for early detection of cognitive impairment and Alzheimer's. Both companies pursue earlier, accessible detection of neurodegenerative decline, but Linus uses digital pen-and-tablet cognitive tests rather than retinal biomarkers.
  • Spectral MD: Spectral MD applies hyperspectral imaging and AI for wound care diagnostics. While the application area differs, the underlying hyperspectral imaging + AI architecture is technically analogous to RetiSpec's approach, making it a relevant technology peer.
  • ADx NeuroSciences: ADx NeuroSciences develops biomarker assays (CSF and blood) for Alzheimer's and other neurodegenerative diseases. Both companies are advancing biomarker-based diagnostics for early Alzheimer's detection, though ADx focuses on biofluid assays rather than retinal imaging.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

RetiSpec social profiles

Digital presence

RetiSpec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RetiSpec leadership team

Management profile

Number of profiles

Profiles8 records

RetiSpec funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RetiSpec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RetiSpec

What does RetiSpec do?

RetiSpec develops an AI-driven diagnostic platform that uses hyperspectral retinal imaging to detect Alzheimer's disease pathology (amyloid beta) years before clinical symptoms emerge. The platform analyzes data from existing retinal imaging cameras already deployed in eye clinics, combining hyperspectral image capture with explainable AI algorithms to deliver non-invasive, point-of-care screening for neurodegenerative disease markers.

Is RetiSpec a public or private company?

RetiSpec is a private company. It is classified as venture growth investor backed and is currently operating.

When was RetiSpec founded?

RetiSpec was founded in 2016. It employs 11 to 50 people.

Where is RetiSpec based?

RetiSpec is headquartered in Toronto, Canada, in the North America region.

How does RetiSpec make money?

One revenue line is on record: pre-revenue / Research Use Only.

Who are RetiSpec's main competitors?

Direct peers on record are C2N Diagnostics, Quanterix, iHealthScreen and Notal Vision. Broad incumbents are Topcon Healthcare, Optos (Nikon) and icometrix. Emerging players are Linus Health, Spectral MD and ADx NeuroSciences.

Does RetiSpec have an API?

No public API is recorded for RetiSpec.

What industry is RetiSpec in?

RetiSpec's product category is Medical Imaging Diagnostics. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 621512.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooRetiSpec secures $10m to accelerate eye test commercialisationRetiSpec closed a $10m Series A led by iGan Partners, bringing total funding to $17m. The company will use the funds to accelerate commercialization of its AI-driven eye test for Alzheimer's detection. It plans to join the Bio-Hermes-002 study and develop additional diagnostics.Forbes5 Reasons Vision Technology Companies Are Building Brands In 2024Vision technology companies are building brands in 2024, driven by AI-enabled screening, smart eyewear, aesthetics, accessibility tech, and bionic eyes. AI startups in eye screening raised over $1.8 billion in equity since 2020, and startups like RetiSpec and Toku Eyes are developing AI-based disease detection.PR NewswireK2 Medical Research Join Forces with Magruder Eye Institute to Advance Alzheimer's Clinical Trial Accessibility Through RetiSpec's AI-Driven Eye TestK2 Medical Research, Magruder Eye Institute, and RetiSpec launched a research pilot to use RetiSpec's AI eye test as a pre-screening tool for Alzheimer's clinical trials. The collaboration aims to reduce recruitment time and expand trial accessibility in eye care settings.WsjIs the Eye the Window to Alzheimer’s?RetiSpec developed an AI algorithm that analyzes eye-scanner results to detect Alzheimer's disease 20 years before symptoms appear. The tool is part of broader efforts by startups and researchers to use AI for early detection of the disease, which affects over seven million Americans.The NationalEye test could detect early signs of Alzheimer's diseaseRetiSpec's AI-assisted eye test can detect early Alzheimer's signs via retinal amyloid imaging. The test is in regulatory approval processes in North America, aiming to enable earlier treatment. Experts note challenges like standardization and data interpretation remain.PR NewswireRETISPEC AND TORONTO MEMORY PROGRAM AWARDED GRANT TO LAUNCH INNOVATIVE EARLY DETECTION PROGRAM FOR ALZHEIMER'S IN TORONTO, CANADARetiSpec and Toronto Memory Program launched an Alzheimer's screening program in Toronto, using RetiSpec retinal scans in optometry clinics and cognitive testing via the Alzheimer Society. The project, funded by the Davos Alzheimer's Collaborative, is one of 12 grant recipients and aims to improve early detection and scale across Canada.BioWorldRetispec develops noninvasive early Alzheimer’s diagnosticRetispec Inc. developed a noninvasive test that can detect early signs of Alzheimer's disease decades before clinical symptoms appear. The test uses off-the-shelf ophthalmic equipment, enabling assessment by optometrists during a standard eye exam.Toronto StarArtificial intelligence is changing how we diagnose disease, triage cases in the ER, even help prep doctorsAI tools are being developed to diagnose diseases and triage emergency cases, including MIMOSA's near-infrared tissue assessment and RetiSpec's eye scan for Alzheimer's biomarkers. Unity Health Toronto's AI algorithm reduced mortality by 20% among high-risk patients. Experts say AI will not replace doctors but those using it will replace those who don't.BostonGlobe.comCan a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?Researchers at Massachusetts General Hospital and Brigham and Women's Hospital are testing RetiSpec's retinal camera to detect Alzheimer's signs in 100 patients over 18 months. The painless test could be cheaper and more accessible than PET scans or spinal taps, which have about 85% accuracy. The study is part of a $2 million NIH-funded project.BetaKitRetiSpec leveraging University of Minnesota tech to detect earlier-stage Alzheimer’sRetiSpec and the University of Minnesota announced a licensing agreement to integrate early Alzheimer's detection technology into RetiSpec's machine learning platform. The technology detected Alzheimer's in mice 25% sooner than plaque-based methods, and a pilot study involved 31 participants. RetiSpec plans a three-site clinical study to test the combined approach.